Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morten Krogh Jensen

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Ugeskrift for Laeger|November 19, 2011
[Treatment of acute myeloid leukaemia without blood transfusion in a member of Jehovah's Witnesses]Christian Larsen, Morten Krogh Jensen
Ugeskrift for Laeger|June 27, 2007
[Primary non-Hodgkin's lymphomas of the central nervous system. Still more questions than answers in the treatment?]Per Boye Hansen, Morten Krogh Jensen
American Journal of Hematology|March 14, 2002
Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disordersMorten Krogh Jensen, Peter de Nully Brown, Sixtus Thorsen, et al.
European Journal of Haematology|April 3, 2014
Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory stateMads Emil Bjørn, Christen Lykkegaard Andersen, Morten Krogh Jensen, et al.
European Journal of Haematology|September 25, 2002
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia veraMorten Krogh Jensen, Rikke Riisbro, Peter de Nully Brown, et al.
The American Journal of Pathology|June 12, 2002
TRAP induces more intense tyrosine phosphorylation than thrombin with differential ultrastructural featuresBerta Fusté, Maribel Díaz-Ricart, Morten Krogh Jensen, et al.
Current Drug Targets|December 15, 2010
Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectivesHans Carl Hasselbalch, Thomas Stauffer Larsen, Caroline Hasselbalch Riley, et al.
Cancer Chemotherapy and Pharmacology|January 4, 2012
Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemiaMikkel Krogh-Madsen, Brendan Bender, Morten Krogh Jensen, et al.
Ugeskrift for Laeger|June 21, 2008
[Novel medical treatment modalities in hematology]Hans Carl Hasselbalch, Henrik Birgens, Inge Høgh Dufva, et al.
European Journal of Haematology|September 3, 2003
Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolismMorten Krogh Jensen, Rikke Riisbro, Mads N Holten-Andersen, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|November 19, 2011
[Treatment of acute myeloid leukaemia without blood transfusion in a member of Jehovah's Witnesses]Christian Larsen, Morten Krogh Jensen
Ugeskrift for Laeger|June 27, 2007
[Primary non-Hodgkin's lymphomas of the central nervous system. Still more questions than answers in the treatment?]Per Boye Hansen, Morten Krogh Jensen
American Journal of Hematology|March 14, 2002
Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disordersMorten Krogh Jensen, Peter de Nully Brown, Sixtus Thorsen, et al.
European Journal of Haematology|April 3, 2014
Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory stateMads Emil Bjørn, Christen Lykkegaard Andersen, Morten Krogh Jensen, et al.
European Journal of Haematology|September 25, 2002
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia veraMorten Krogh Jensen, Rikke Riisbro, Peter de Nully Brown, et al.
The American Journal of Pathology|June 12, 2002
TRAP induces more intense tyrosine phosphorylation than thrombin with differential ultrastructural featuresBerta Fusté, Maribel Díaz-Ricart, Morten Krogh Jensen, et al.
Current Drug Targets|December 15, 2010
Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectivesHans Carl Hasselbalch, Thomas Stauffer Larsen, Caroline Hasselbalch Riley, et al.
Cancer Chemotherapy and Pharmacology|January 4, 2012
Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemiaMikkel Krogh-Madsen, Brendan Bender, Morten Krogh Jensen, et al.
Ugeskrift for Laeger|June 21, 2008
[Novel medical treatment modalities in hematology]Hans Carl Hasselbalch, Henrik Birgens, Inge Høgh Dufva, et al.
European Journal of Haematology|September 3, 2003
Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolismMorten Krogh Jensen, Rikke Riisbro, Mads N Holten-Andersen, et al.
Pageof 2